Welcome to our dedicated page for HAVN LIFE SCIENCES news (Ticker: HAVLF), a resource for investors and traders seeking the latest updates and insights on HAVN LIFE SCIENCES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HAVN LIFE SCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HAVN LIFE SCIENCES's position in the market.
HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) will be featured on Viewpoint with Dennis Quaid, airing in July on over 170 public television stations in the U.S., reaching 60 million households. CEO Tim Moore, along with other executives, will discuss the company's advancements in psychedelic medicine and its partnerships. The segment aims to educate on the potential of psilocybin therapies. Additionally, HAVN Life will air a commercial on Fox Business up to 400 times this year. Recently, the company granted stock options to executives at $0.06 each.
HAVN Life Sciences Inc. (CSE:HAVN, OTC:HAVLF) will present at the Planet MicroCap Showcase 2022 on May 4, 2022, at 9:00 a.m. PST in Las Vegas, NV. Tim Moore, CEO, will lead the presentation, answering investor questions. Interested parties can access the live webcast here. Attendees can also schedule 1on1 meetings at the conference. For those unable to attend, all presentations will be available on the conference platform under the “Agenda” tab.
HAVN Life Sciences Inc. (CSE: HAVN, OTC: HAVLF) has secured a purchase order for GMP psilocybin extract from Revive Therapeutics Ltd. for research purposes at the University of Wisconsin-Madison. This collaboration aims to advance investigations into psychedelic-assisted therapies for mental health disorders. The export will be facilitated by Mycrodose Therapeutics Inc., leveraging their DEA authorization to distribute psilocybin for research. CEO Tim Moore emphasized the potential for this research to reshape treatment accessibility and address the mental health crisis.
Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF) has finalized a partnership with Mycrodose Therapeutics, advancing its strategy to enter the U.S. market. This collaboration enables HAVN Life to export naturally derived psilocybin for advanced drug delivery systems aimed at treating mental health disorders. Mycrodose is uniquely permitted by the DEA to manage psilocybin distribution. This agreement addresses supply chain challenges for U.S. pharmaceutical firms and institutions, allowing access to affordable psilocybin. The partnership positions HAVN Life as a leader in the emerging psychedelics sector.
Havn Life Sciences has announced a strategic partnership with Horizon Grocery + Wellness, enhancing its distribution network for natural health products. This collaboration will enable Havn Life to reach a wider retail audience, with the first purchase order anticipated in early November. The distribution deal aims to streamline supply chains and boost sales for Havn Life's non-GMO, vegan products formulated to enhance brain health. In addition, another partnership with Well.ca has been established, fortifying its online presence in the health product market.
Havn Life Sciences (CSE:HAVN)(OTC:HAVLF) has announced a partnership with Mycotopia Therapies to supply naturally-derived psilocybin for their psychedelic therapies targeting mental health issues such as anxiety and depression. This agreement highlights Havn's commitment to providing quality psilocybin medicine to researchers and patients globally. The psilocybin will be sourced from Havn's Jamaican facility, in collaboration with Hypha Wellness, enhancing distribution efficiency. CEO Tim Moore emphasized the alignment of both companies in advancing brain health.
HAVN Life Sciences has successfully harvested its first crop of psilocybin mushrooms from its facility in Jamaica, marking a significant milestone in the company's strategy. The harvested product will be exported to Delic Labs in Canada for quality control and testing, positioning HAVN Life as the first exporter of psilocybin within the Caribbean Community and Common Market. This partnership aims to enhance the safety and quality of psychedelics for research and clinical applications across North America, the Caribbean, and Europe.
Havn Life Sciences Inc. has received Fulfilled by Amazon (FBA) designation for its new line of natural health products, now available on Amazon.ca. This move expands Havn Life's retail presence, allowing products to be shipped across Canada. CEO Tim Moore expressed optimism about the partnership, emphasizing the platform's vast reach. Havn Life's products, which include adaptogens and antioxidants, support brain health and cognitive function. They are also sold through the company's ecommerce site and select retail stores.
Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF) has announced a significant agreement with P.A. Benjamin Manufacturing Company, a GMP compliant facility in Jamaica, for the contract packing of naturally-derived psilocybin. This partnership enhances HAVN's position in the burgeoning psychedelic market and opens pathways for exports to Canada, the US, and Europe. The collaboration, aligned with local stakeholders, aims to ensure safe, quality-controlled psilocybin API supplies for research and therapeutic purposes, marking a pivotal step in establishing HAVN as a leader in the international psychedelic supply chain.
Havn Life Sciences (CSE:HAVN, OTC PINK:HAVLF) has announced a new supply agreement with Cube Psytech, a biopharmaceutical firm focused on psilocybin microdosing health products. The collaboration will leverage Havn Life's mushroom cultivation operations in Jamaica and supports Cube Psytech's development of products compliant with Health Canada guidelines. CEO Tim Moore emphasized their commitment to meeting the growing demand for naturally-derived psilocybin, while Cube Psytech's CEO expressed confidence in Havn Life as a reliable supplier.
FAQ
What is the market cap of HAVN LIFE SCIENCES (HAVLF)?
